<!DOCTYPE html>
<html lang="en-us">
  <head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    
    <title>Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma | Fallingstar Daily R</title>
    <link rel="stylesheet" href="/css/style.css" />
    <link rel="stylesheet" href="/css/fonts.css" />
    <link href="//cdn.bootcss.com/highlight.js/9.12.0/styles/github.min.css" rel="stylesheet">

  </head>

  <body class="page">
    <nav class="header">
      <div class="banner">
<a href="/" class="text">
&Ffr;&Afr;&Lfr;&Lfr;&Ifr;&Nfr;&Gfr;&Sfr;&Tfr;&Afr;&Rfr; &Dfr;&Afr;&Ifr;&Lfr;&Yfr; &Rfr;
</a>
</div>

      <div class="head-meta">
      
        <span><a href="/">&larr; Back to Home</a></span>
        <span class="date">2024-12-09</span>
        
        
        
          
        
        
        <span><a href="https://github.com/rainoffallingstar/daily-rss/edit/master/content/post/pubmed-ncbi-nlm-nih-gov-39652675-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241209184155-v-2-18-0-post9-.md">Edit this page &rarr;</a></span>
        
        
      
      </div>
    </nav>

<div class="container">
<article>
<div class="article-meta">

  <div class="categories">
  
  </div>

  <h1><span class="title">Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma</span></h1>

  

  
  

</div>



<main>
<p>CONCLUSIONS: Among patients with high-risk smoldering multiple myeloma, subcutaneous daratumumab monotherapy was associated with a significantly lower risk of progression to active multiple myeloma or death and with higher overall survival than active monitoring. No unexpected safety concerns were identified. (Funded by Janssen Research and Development; AQUILA ClinicalTrials.gov number, &hellip;</p>

<script>
var url = "https://pubmed.ncbi.nlm.nih.gov/39652675/?utm_source=curl\u0026utm_medium=rss\u0026utm_campaign=pubmed-2\u0026utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V\u0026fc=20220326224207\u0026ff=20241209184155\u0026v=2.18.0.post9+e462414";
var strReg = "http|https";
var re = new RegExp(strReg);
setTimeout(function() { if(re.test(url)) {window.location.href = url} }, 10000);
</script>
</main>




<nav class="post-nav">
  <span class="nav-prev"><a href="/post/pubmed-ncbi-nlm-nih-gov-39652594-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241209184155-v-2-18-0-post9-/">&larr; Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial</a></span>
  <span class="nav-next"><a href="/post/pubmed-ncbi-nlm-nih-gov-39652675-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20241209184143-v-2-18-0-post9-/">Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma &rarr;</a></span>
</nav>




</article>
</div>

<script async src="//yihui.name/js/center-img.js"></script>

<footer>

<div class="footer">
  <ul class="menu">
    
    <li><a href="/"><span data-hover="Home">Home</span></a></li>
    
    <li><a href="/about/"><span data-hover="About">About</span></a></li>
    
    <li><a href="/archives/"><span data-hover="Archive">Archive</span></a></li>
    
    <li><a href="/contributor/"><span data-hover="Contributor">Contributor</span></a></li>
    
    <li><a href="/index.xml"><span data-hover="Subscribe">Subscribe</span></a></li>
    
  </ul>
  
  <div class="copyright">Â© <a href="https://rainoffallingstar.github.io">Fallingstar</a> 2023 | <a href="https://github.com/rainoffallingstar">Github</a></div>
  
</div>
</footer>







</body>
</html>

